Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Chalfant

Psychiatry Belleville, IL Doctor of Osteopathy

NPI 1811935166 CMS profile 173442

2900 Frank Scott Pkwy W, Suite 990, Belleville, IL 62223

Open in the dashboard

General payments

$6,338

657 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Chalfant of Belleville, IL is reported in the CMS Open Payments database as having received $6,338 across 657 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,066 89
2024 General $963 71
2023 General $758 72
2022 General $505 42
2021 General $993 109
2020 General $913 94
2019 General $1,140 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Chalfant
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jeffrey Chalfant were reported at $1,066. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jeffrey Chalfant Psychiatry median Middle half National median
2019 $1,140 $184 $59–$605 $163
2020 $913 $119 $36–$372 $114
2021 $993 $143 $43–$576 $132
2022 $505 $153 $50–$590 $149
2023 $758 $170 $56–$651 $160
2024 $963 $179 $57–$673 $164
2025 $1,066 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,070 144 payments
  2. AbbVie, Inc. $851 75 payments
  3. Lundbeck LLC $795 85 payments
  4. ITI, Inc. $768 79 payments
  5. Teva Pharmaceuticals USA, Inc. $600 44 payments
  6. Allergan Inc. $574 78 payments
  7. Sunovion Pharmaceuticals Inc. $433 54 payments
  8. Neos Therapeutics, LP $327 32 payments
  9. Otsuka America Pharmaceutical, Inc. $287 19 payments
  10. Tris Pharma Inc $163 19 payments
  11. Other $472 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,169 652 payments
  2. Education $169 5 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $755 97 payments
  2. TRINTELLIX $701 73 payments
  3. VRAYLAR Neuroscience $657 54 payments
  4. REXULTI $553 54 payments
  5. CAPLYTA $529 53 payments
  6. LATUDA $418 53 payments
  7. Austedo XR $365 32 payments
  8. Adzenys XR-ODT $310 31 payments
  9. COTEMPLA XR-ODT $310 31 payments
  10. BRINTELLIX $242 31 payments
  11. Other $1,945 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

5,518

Median for Psychiatry: 574

Drug cost

$316,552

Median for Psychiatry: $27,624

Branded share of claims

23.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 14 $150,511
Vraylar Cariprazine Hcl Brand 15 $21,301
Rexulti Brexpiprazole Brand 11 $19,100
Trintellix Vortioxetine Hydrobromide Brand 28 $15,244
Aripiprazole Generic 221 $11,308
Bupropion Xl Bupropion Hcl Brand 417 $7,655
Paliperidone Er Paliperidone Brand 21 $7,018
Duloxetine Hcl Generic 292 $6,781
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 142 $6,163
Vyvanse Lisdexamfetamine Dimesylate Brand 11 $4,328

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$63,032

Medicare's payments for the services billed

Medicare patients

228

Average age 67

Services billed

1,034

152 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 73%
High blood pressure 71%
Arthritis 54%
Diabetes 34%
Ischemic heart disease 24%
Chronic kidney disease 22%
COPD 20%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $246
$246 15 —
CAPLYTA
  • ITI, Inc. $174
$174 — —
Dyanavel XR
  • Tris Pharma Inc $147
$147 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $100
$100 14 —
Auvelity
  • Axsome Therapeutics, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

657 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record